Associated Papers
Pharmacokinetic recall study of Estonian Biobank participants with novel genetic variants in CYP2C19 and CYP2D6.
Krebs K et al.
Npj Genomic Medicine, 2026
Natural Polymorphic Variants in the CYP450 Superfamily: A Review of Potential Structural Mechanisms and Functional Consequences.
Prost R et al.
International Journal of Molecular Sciences, 2025
Pharmacogenetic pilot study of CYP2D6 and CYP1A2 genes in Italian patients with non-dystrophic myotonia and myotonic dystrophy treated with mexiletine.
Brugnoni R et al.
Gene, 2025
Improved Prediction of CYP2D6 Catalyzed Drug Metabolism by Taking Variant Substrate Specificities and Novel Polymorphic Haplotypes into Account.
Johansson I et al.
Clinical Pharmacology and Therapeutics, 2025
Contrastive sequence signatures between the both sides of a recombination spot reveal an adaptation at PPARD locus from standing variation for pleiotropy since out-of-Africa dispersal.
Shou W et al.
Bmc Genomics, 2025
The impact of CYP2D6 on donepezil concentration and its lack of effect on the treatment response and adverse effect in Korean patients with Alzheimer's disease.
Kim TE et al.
The Korean Journal of Physiology & Pharmacology : Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology, 2025
In vitro comparative analysis of metabolic capabilities and inhibitory profiles of selected CYP2D6 alleles on tramadol metabolism.
Nahid NA et al.
Clinical and Translational Science, 2025
PharmFreq: a comprehensive atlas of ethnogeographic allelic variation in clinically important pharmacogenes.
Tremmel R et al.
Nucleic Acids Research, 2025
Value of Pharmacogenetic Testing Assessed with Real-World Drug Utilization and Genotype Data.
Litonius K et al.
Clinical Pharmacology and Therapeutics, 2025
Catalogue of Somatic Mutations in Cancer Database and Structural Modeling Analysis of CYP2D6 Mutations in Human Cancers.
Kuchinski K et al.
The Journal of Pharmacology and Experimental Therapeutics, 2024
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP2C19 and non-SSRI/non-TCA antidepressants.
Beunk L et al.
European Journal of Human Genetics : Ejhg, 2024
Loss of heterozygosity of CYP2D6 enhances the sensitivity of hepatocellular carcinomas to talazoparib.
Zhang X et al.
Ebiomedicine, 2024
Molecular Mechanisms Underlying Single Nucleotide Polymorphism-Induced Reactivity Decrease in CYP2D6.
Becker D et al.
Journal of Chemical Information and Modeling, 2024
The Frequency of CYP2D6 and CYP3A4/5 Genotypes and The Impact of Their Allele Translation and Phenoconversion-Predicted Enzyme Activity on Risperidone Pharmacokinetics in Saudi Children with Autism.
Shilbayeh SAR et al.
Biochemical Genetics, 2024
The variation landscape of CYP2D6 in a multi-ethnic Asian population.
Maulana Y et al.
Scientific Reports, 2024
APF2: an improved ensemble method for pharmacogenomic variant effect prediction.
Zhou Y et al.
The Pharmacogenomics Journal, 2024
A New Cloud-Native Tool for Pharmacogenetic Analysis.
Yuan DY et al.
Genes, 2024
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6, CYP3A4 and CYP1A2 and antipsychotics.
Beunk L et al.
European Journal of Human Genetics : Ejhg, 2024
Leveraging in Vitro Models for Clinically Relevant Rare CYP2D6 Variants in Pharmacogenomics.
Stern S et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2024
Stimulatory and Inhibitory Effect of Antipsychotic Agents Including Dopaminergic Neuro-depressants on Dopamine Formation from p-tyramine Mediated by Cytochrome P450 2D6.
Niwa T et al.
Drug Metabolism and Bioanalysis Letters, 2024
[Metabolic Activities Catalyzed by Human Cytochrome P450 (CYP) 2D6 and CYP3A Subfamily Members and Effect of Various Compounds, Including Endogenous Steroid Hormones, on These Activities].
Niwa T
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan, 2024
Effect of donor GSTM3 rs7483 genetic variant on tacrolimus elimination in the early period after liver transplantation.
Zhang T et al.
Peerj, 2024
Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of CYP2D6 and COMT with atomoxetine and methylphenidate.
Nijenhuis M et al.
European Journal of Human Genetics : Ejhg, 2023
Using population pharmacokinetic analyses of drugs metabolized by CYP2D6 to study the genotype-phenotype translation.
Frederiksen T
Basic & Clinical Pharmacology & Toxicology, 2023
At-Risk Genomic Findings for Pediatric-Onset Disorders From Genome Sequencing vs Medically Actionable Gene Panel in Proactive Screening of Newborns and Children.
Balciuniene J et al.
Jama Network Open, 2023
Determination of the Duplicated CYP2D6 Allele Using Real-Time PCR Signal: An Alternative Approach.
Atiq MA et al.
Journal of Personalized Medicine, 2023
Characterization of CYP2D6 Pharmacogenetic Variation in Sub-Saharan African Populations.
Twesigomwe D et al.
Clinical Pharmacology and Therapeutics, 2023
Deep genomic analysis of malignant peripheral nerve sheath tumor cell lines challenges current malignant peripheral nerve sheath tumor diagnosis.
Magallón-Lorenz M et al.
Iscience, 2023
Human Cytochrome P450 1, 2, 3 Families as Pharmacogenes with Emphases on Their Antimalarial and Antituberculosis Drugs and Prevalent African Alleles.
Chamboko CR et al.
International Journal of Molecular Sciences, 2023
Estimating the In Vivo Function of CYP2D6 Alleles through Population Pharmacokinetic Modeling of Brexpiprazole.
Frederiksen T et al.
Clinical Pharmacology and Therapeutics, 2023
Computational pharmacogenotype extraction from clinical next-generation sequencing.
Shugg T et al.
Frontiers in Oncology, 2023
A frequent CYP2D6 variant promotes skipping of exon 3 and reduces CYP2D6 protein expression in human liver samples.
Collins JM et al.
Frontiers in Pharmacology, 2023
Targeted haplotyping in pharmacogenomics using Oxford Nanopore Technologies' adaptive sampling.
Deserranno K et al.
Frontiers in Pharmacology, 2023
CYP2D6 and CYP2C19 Genes Associated with Tricontinental and Latin American Ancestry of Pe-ruvians.
Alvarado AT et al.
Drug Metabolism and Bioanalysis Letters, 2022
Association of Inherited Genetic Factors With Drug-Induced Hepatic Damage Among Children With Acute Lymphoblastic Leukemia.
Yang W et al.
Jama Network Open, 2022
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data.
Zhou Y et al.
The Pharmacogenomics Journal, 2022
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2D6 and opioids (codeine, tramadol and oxycodone).
Matic M et al.
European Journal of Human Genetics : Ejhg, 2022
Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction between CYP2C19 and CYP2D6 and SSRIs.
Brouwer JMJL et al.
European Journal of Human Genetics : Ejhg, 2022
Characterization of Novel CYP2D6 Alleles across Sub-Saharan African Populations.
Wang WY et al.
Journal of Personalized Medicine, 2022
Effect of Human Cytochrome P450 2D6 Polymorphism on Progesterone Hydroxylation.
Niwa T et al.
European Journal of Drug Metabolism and Pharmacokinetics, 2022
The potential impact of CYP2D6 (*2/*4/*10) gene variants among Egyptian epileptic children: A preliminary study.
Elsaid AM et al.
Gene, 2022
Folate Related Pathway Gene Analysis Reveals a Novel Metabolic Variant Associated with Alzheimer's Disease with a Change in Metabolic Profile.
Miyan J et al.
Metabolites, 2022
Transgenic HepaRG cells expressing CYP2D6 as an improved model of primary human hepatocytes.
Okuyama S et al.
Pharmacology Research & Perspectives, 2022
Clinical pharmacogenomic testing and reporting: A technical standard of the American College of Medical Genetics and Genomics (ACMG).
Tayeh MK et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics, 2022
CYP2D6 gene resequencing in the Malagasy, a population at the crossroads between Asia and Africa: a pilot study.
Chan ER et al.
Pharmacogenomics, 2022